At the forefront of biomedical innovation, our research line on Early Disease Detection is dedicated to understanding the earliest molecular and cellular changes that mark the transition from health to disease. By deciphering these initial alterations, we aim to pave the way for groundbreaking advancements in medical diagnostics and preventive care.
Our primary objective is to delve deep into the biological processes that cause a cell to deviate from its healthy state, ultimately leading to disease onset. By identifying novel biomarkers through the study of molecular heterogeneity within patient cells, we strive to develop early detection tools that can intervene before symptoms appear, offering a critical window of opportunity for treatment.

To achieve these goals, we leverage cutting-edge technology platforms, including single-cell and spatial technologies, laser micro-dissection, high-throughput DNA sequencing, and mass spectrometry. These tools enable us to gather comprehensive data sets from patient samples, capturing the intricate molecular landscape that precedes disease.
Our research does not stop at data collection. We employ advanced statistical methods and machine learning algorithms to interpret this vast array of information. By correlating molecular changes with tissue and organ abnormalities, we can trace the path of disease progression, ultimately leading to the discovery of precise biomarkers for early detection.

Our mission is to revolutionize healthcare by detecting diseases at their inception, where intervention can be most effective, and lives can be transformed.

In the quest to revolutionize how we understand and treat diseases, our research line on Creation of Novel Disease Models is pushing the boundaries of biomedical science. By developing innovative in vitro models that closely replicate human physiology, we aim to create powerful tools for uncovering the mechanisms of disease and accelerating the discovery of new therapies.

Our goal is to establish physiologically relevant disease models using human cells and tissues derived from patients. These models serve as invaluable platforms for studying the intricate processes of disease progression in a controlled environment, providing insights that are directly translatable to patient care.

To achieve these objectives, we are at the forefront of developing cutting-edge protocols for generating organoid cultures or organ-on-chip systems. These microphysiological systems, derived from both healthy and diseased cells, are designed to mimic the complex processes of cell differentiation, tissue composition, and organ physiology found in vivo. By replicating the progression of disease within these models, we can closely study the biological changes that occur, enabling the identification of novel therapeutic targets.

Our approach is deeply integrated with the advanced technologies used in our early disease detection projects, ensuring a comprehensive characterization of the models we create. We employ a range of techniques, including single-cell and spatial technologies, high-throughput DNA sequencing, and mass spectrometry, to analyze these models in detail.

Finally, we intent to assess the predictive power of our models by comparing their therapeutic responses to those observed in actual patients. This evaluation is crucial for validating the models as reliable tools for drug testing and personalized medicine.

We want to lead the charge in creating next-generation disease models that are set to transform therapeutic discovery and pave the way for more effective treatments tailored to individual patients.

In the quest to revolutionize how we understand and treat diseases, our research line on Creation of Novel Disease Models is pushing the boundaries of biomedical science. By developing innovative in vitro models that closely replicate human physiology, we aim to create powerful tools for uncovering the mechanisms of disease and accelerating the discovery of new therapies.

Our goal is to establish physiologically relevant disease models using human cells and tissues derived from patients. These models serve as invaluable platforms for studying the intricate processes of disease progression in a controlled environment, providing insights that are directly translatable to patient care.

To achieve these objectives, we are at the forefront of developing cutting-edge protocols for generating organoid cultures or organ-on-chip systems. These microphysiological systems, derived from both healthy and diseased cells, are designed to mimic the complex processes of cell differentiation, tissue composition, and organ physiology found in vivo. By replicating the progression of disease within these models, we can closely study the biological changes that occur, enabling the identification of novel therapeutic targets.

Our approach is deeply integrated with the advanced technologies used in our early disease detection projects, ensuring a comprehensive characterization of the models we create. We employ a range of techniques, including single-cell and spatial technologies, high-throughput DNA sequencing, and mass spectrometry, to analyze these models in detail.

Finally, we intent to assess the predictive power of our models by comparing their therapeutic responses to those observed in actual patients. This evaluation is crucial for validating the models as reliable tools for drug testing and personalized medicine.

We want to lead the charge in creating next-generation disease models that are set to transform therapeutic discovery and pave the way for more effective treatments tailored to individual patients.